Status and progress of hepatitis B control through vaccination in the South-East Asia Region, 1992–2015
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In 2016, the Immunization Technical Advisory Group of the South-East Asia Region (SEAR) endorsed a regional goal to achieve ≤1% prevalence of hepatitis B surface antigen (HBsAg) among 5-year-old children by 2020. Chronic hepatitis B virus (HBV) infection is largely preventable with a birth dose of hepatitis B vaccine (HepB-BD) followed by two to three additional doses. We reviewed the progress towards hepatitis B control through vaccination in SEAR during 1992–2015. We summarized hepatitis B vaccination data and reviewed the literature to determine the prevalence of chronic HBV infection pre- and post-vaccine introduction. We used a mathematical model to determine post-vaccine prevalence of HBsAg among 5 year olds in countries lacking national serosurvey data and estimated the impact of vaccination on disease burden. Regional coverage with three doses of hepatitis B vaccine (HepB3) increased from 56% in 2011 to 87% in 2015. By 2016, 7 of 11 countries had introduced universal HepB-BD. Regional HepB-BD coverage increased from 9% in 2011 to 34% in 2015. In 2015, estimated HBsAg among 5 year olds was 1.1% with variability among countries. Myanmar (3.8%), Timor-Leste (2.7%), Indonesia (1.8%), and India (1%) had the highest prevalence of HBsAg. During 1992–2015, vaccination prevented approximately 16 million chronic HBV infections and 2.6 million related deaths. In 2015, around 197,640 perinatal HBV infections occurred in SEAR with majority occurring in India (62%), Bangladesh (24%), and Myanmar (8%). Myanmar had the highest rate of perinatal chronic HBV infections at 16 per 1000 live births. Despite significant progress in the control of HBV, SEAR needs to secure political commitment for elimination and consider additional strategies, such as promoting health facility births, universal birth dose administration, developing strong coordination between health sectors, and using alternative vaccine delivery methods, to improve HepB-BD coverage and subsequently achieve HBV control and elimination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A mathematical model to estimate global hepatitis B disease burden and vaccination impact.
Goldstein, S. T., Zhou, F., Hadler, S. C., Bell, B. P., Mast, E. E., & Margolis, H. S. (2005) · International Journal of Epidemiology · doi:10.1093/ije/dyi206 · Cited by 743
Cited by
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“Despite the presence of an efficient vaccine, chronic HBV infection still affects currently approximately 260 million people, mostly in Africa and Asia [188].”
BackgroundPattyn, J., Hendrickx, G., Vorsters, A., & Van Damme, P. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa668 · Cited by 282
Bierhoff, M., Pinyopornpanish, K., Pinyopornpanish, K., Tongprasert, F., Keereevijit, A., Rijken, M., Chu, C. S., Nosten, F., Perfetto, J., van Vugt, M., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz518 · Cited by 17
Basa, J. E., Clemens, R., Clemens, S. A. C., & Nicholson, M. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.02.047 · Cited by 5
Metadata
- Authors
- Childs, L., Roesel, S., & Tohme, R. A.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 36
- Issue
- 1
- Pages
- 6-14
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2768469124
- Cited by
- 82
- References
- 2
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Status and progress of hepatitis B control through vaccination in the South-East Asia Region, 1992–2015. https://app.cochat.ai/papers/10.1016/j.vaccine.2017.11.027
- The paper
- Childs, L., Roesel, S., & Tohme, R. A. (2018). Status and progress of hepatitis B control through vaccination in the South-East Asia Region, 1992–2015. Vaccine. https://doi.org/10.1016/j.vaccine.2017.11.027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.